Comorbid pathology in the forensic psychiatric clinic: personality disorder and psychoactive substance dependence
Suggested citation:
Gorinov VV, Korzun DN. [Comorbid pathology in the forensic psychiatric clinic: personality disorder and psychoactive substance dependence]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2019;(2):36-42. Russian
This scientific review pursued the objective of systematizing in carrying out the analysis of the results of studies that looked at those personality disorders which predispose one to develop a psychoactive substance dependence. We have generalized the data obtained in the course of assessing the patients, suffering from personality disorders and the comorbid psychoactive substance dependence syndrome, on the scales of impulsiveness, aggressiveness, and suicidal intentions, depending on the kind of psychoactive substance which they used. We have compared the identified disturbances of self-image and fundamental convictions, emotions and motivation, with the criteria for limited responsibility, which have been developed to date.
Keywords personality disorder; syndrome of dependence; psychoactive substances; comorbidity; criminal responsibility; limited responsibility
1. Tomko RL, Trull TJ, Wood PK, Sher KJ. Characteristics of borderline personality disorder in a community sample: Comorbidity, treatment utilization, and general functioning. J Pers Disord. 2014;28:734–50. PMID: 25248122, PMCID: PMC3864176, DOI: 10.1521/pedi_2012_26_093 2. Dom G, Moggi F. Co-occurring Addictive and Psychiatric Disorders. Berlin, Heidelberg: Springer; 2016;137–48. 3. Belcher AM, Volkow ND, Moeller FG, Ferré S. Personality traits and vulnerability or resilience to substance use disorders. Trends Cogn Sci. 2014;18:211–7. PMID: 24612993, PMCID: PMC3972619, DOI: 10.1016/j.tics.2014.01.010 4. Swann NC, Cai W, Conner CR, et al. Roles for the pre-supplementary motor area and the right inferior frontal gyrus in stopping action: Electrophysiological responses and functional and structural connectivity. Neuroimage. 2012;59:2860–70. PMID: 21979383, PMCID: PMC3322194, DOI: 10.1016/j.neuroimage.2011.09.049 5. Tabibnia G, Monterosso JR, Baicy K, et al. Different forms of self-control share a neurocognitive substrate. J Neurosci. 2011;31:4805–10. PMID: 21451018, PMCID: PMC3096483, DOI: 10.1523/JNEUROSCI.2859-10.2011 6. Ersche KD, Jones PS, Williams GB, et al. Abnormal brain structure implicated in stimulant drug addiction. Science. 2012;335:601–4. PMID: 22301321, DOI: 10.1126/science.1214463 7. González S, Rangel-Barajas C, Peper M, et al. Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain. Mol Psychiatry. 2012;17:650–62. PMID: 21844870, PMCID: PMC3219836, DOI: 10.1038/mp.2011.93 8. Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron. 2012;76:470–85. PMID: 23141060, PMCID: PMC4450094, DOI: 10.1016/j.neuron.2012.10.021 9. Baik SH, Yoon HS, Kim SE, Kim SH. Extraversion and striatal dopaminergic receptor availability in young adults: An [18F] fallypride PET study. Neuroreport. 2012;23:251–4. PMID: 22257904, DOI: 10.1097/WNR.0b013e3283507533 10. Tull MT, Gratz KL. The impact of borderline personality disorder on residential substance abuse treatment dropout among men. Drug Alcohol Depend. 2012;121:97–102. PMID: 21907503, PMCID: PMC3237890, DOI: 10.1016/j.drugalcdep.2011.08.014 11. Fenton MC, Keyes K, Geier T, et al. Psychiatric comorbidity and the persistence of drug use disorders in the United States. Addiction. 2012;107:599–609. PMID: 21883607, PMCID: PMC3260401, DOI: 10.1111/j.1360-0443.2011.03638.x 12. Balhara YP, Parmar A, Sarkar S, Verma R. Stigma in dual diagnosis: A narrative review. Indian J Soc Psychiatr. 2016;32:128–33. 13. Mokhon'ko AR, Makushkin EV, Mugantseva LA. [Key performance indicators of the forensic psychiatric expert service of the Russian Federation in 2017]. Moscow; 2018. p. 107–10. Russian. 14. Ball SA, Maccarelli LM, LaPaglia DM, Ostrowski MJ. Randomized trial of dual-focused versus single-focused individual therapy for PD and substance dependence. J Nerv Ment Dis. 2011;199:319–28. PMID: 21543951, DOI: 10.1097/NMD.0b013e3182174e6f 15. Parmar A, Sarkar S. Brief interventions for cannabis use disorders: A review. Addict Disord Their Treat. 2017;16:80–93. 16. Thylstrup B, Schrøder S, Hesse M. Psycho-education for substance use and ASPD: A randomized trial. BMC Psychiatry. 2015;15:283. PMID: 26573140, DOI: 10.1186/s12888-015-0661-0 17. Thylstrup B, Schrøder S, Fridell M, Hesse M. Did you get any help? A post-hoc secondary analysis of a randomized controlled trial of psychoeducation for patients with ASPD in outpatient substance abuse treatment programs. BMC Psychiatry. 2017;17:7. PMID: 28068951, DOI: 10.1186/s12888-016-1165-2 18. Gianoli MO, Jane JS, O’brien E, Ralevski E. Treatment for comorbid borderline personality disorder and alcohol use disorders: A review of the evidence and future recommendations. Exp Clin Psychopharmacol. 2012;20:333–44. PMID: 22686496, PMCID: PMC3697118, DOI: 10.1037/a0027999 19. Stuyt EB. Ear acupuncture for co-occurring substance abuse and borderline personality disorder: An aid to encourage treatment retention and tobacco cessation. Acupunct Med. 2014;32:318–24. PMID: 24824499, DOI: 10.1136/acupmed-2014-010540
DOI: http://dx.doi.org/10.24411/1560-957X-2019-11918
Article Metrics
Metrics powered by PLOS ALM